Search by Drug Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y ZClinical Trials for FLUTAMIDE
- Contributions to Hypertension With Androgen Deprivation Therapy
- Evaluation of Efficacy of Topical Flutamide in the Treatment of Acne Vulgaris
- Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score
- Androgen Blockade and Progesterone Augmentation of Gonadotropin Secretion
- Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial
- Combination Therapy With Isotretinoin and Tamoxifen Expected to Provide Complete Protection Against Severe Acute Respiratory Syndrome Coronavirus
- Assessment the Activity Value of Isotretinoin (13- Cis-Retinoic Acid ) in the Treatment of COVID-19 ( Isotretinoin in Treatment of COVID-19) (Randomized)
- Androgen Deprivation Therapy on Bone Mineral Density Change in Prostate Cancer Patients
- Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer
- Assessing Induction of Double Strand Breaks With Androgen Receptor Partial Agonist in Patients on Androgen Suppression
- Antiandrogen Therapy and Radiation Therapy With or Without Docetaxel in Treating Patients With Prostate Cancer That Has Been Removed by Surgery
- Study on Enzalutamide and Flutamide in Patients With Castration Resistant Prostate Cancer
- Adipose Tissue Derived Stem Cell Based Hair Restoration Therapy for Androgenetic Alopecia
- Androgen Deprivation Therapy or Androgen Deprivation Therapy Plus Definitive Treatment (Radiation or Surgery)
- Effect of Increased Circulating Androgens on Granulosa Cell Responses to FSH.
- Comparative Study of Alternative Antiandrogen (AA) Therapy and Early Initiating of Enzalutamide for Castration-resistant Prostate Cancer (CRPC) After Combined Androgen Blockade (CAB) Therapy.
- A Study of 2-hydroxyflutamide (Liproca Depot), Injected Into the Prostate in Patients With Localized Prostate Cancer
- Therapeutic Equivalence Between Branded and Generic WARFArin Tablets in Brazil
- Androgen Excess as a Cause for Adipogenic Dysfunction in PCOS Women
- Enzalutamide in Combination With PSA-TRICOM in Patients With Non-Metastatic Castration Sensitive Prostate Cancer
- Finite Androgen Ablation With or Without Abiraterone Acetate and Prednisone in Treating Patients With Recurrent Prostate Cancer
- Cabozantinib Plus Docetaxel and Prednisone for Advanced Prostate Cancer
- Hormone Therapy, Radiation Therapy, and Steroid 17alpha-monooxygenase TAK-700 in Treating Patients With High-Risk Prostate Cancer
- Effects of Androgen Blockade on Sensitivity of the GnRH Pulse Generator to Suppression by Estradiol and Progesterone
- Leuprorelin Associated With Radiotherapy Versus Leuprorelin Alone in T3 - T4 or pT3 (on Biopsy) N0, M0 Prostate Cancer
- Treatment of Hot Flushes Caused by Leuprorelin 11.25 mg in Prostate Adenocarcinoma
- Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer
- Effect of High Testosterone on Sleep-associated Slowing of Follicular Luteinizing Hormone (LH) Frequency in Polycystic Ovary Syndrome
- Intermittent Hormonal Therapy With Leuprorelin and Flutamide in the Treatment of Stage D2 or TxNxM1b,c
- Radiation Therapy and Hormone Therapy in Treating Patients With Prostate Cancer
- Goserelin, Flutamine, and Radiation Therapy in Treating Patients With Locally Advanced Prostate Cancer
- Effects of Flutamide on Insulin and Glucose Metabolism in Women With Polycystic Ovary Syndrome
- Effect of Flutamide on Biomarkers in Blood and Tissue Samples From Patients at High Risk of Ovarian Cancer
- Androgen Suppression and Radiation With/Out Docetaxel in High-Risk Localized Prostate Cancer
- Effectiveness of Flutamide in Treating Women With Premenstrual Dysphoric Disorder
- Prostate Radiation Therapy or Short-Term Androgen Deprivation Therapy and Pelvic Lymph Node Radiation Therapy With or Without Prostate Radiation Therapy in Treating Patients With a Rising Prostate Specific Antigen (PSA) After Surgery for Prostate Ca
- Radiation Therapy, Androgen Suppression, and Docetaxel in Treating Patients With High-Risk Prostate Cancer Who Have Undergone Radical Prostatectomy
- Hormone Therapy and Temsirolimus in Treating Patients With Relapsed Prostate Cancer
- Vaccine Therapy With PROSTVAC/TRICOM and Flutamide Versus Flutamide Alone to Treat Prostate Cancer
- Metabolic Syndrome in PCOS: Precursors and Interventions
- External Beam Radiation Therapy (EBRT) With or Without Hormonal Therapy in Prostate Cancer
- Hormone Therapy and Radiation Therapy or Hormone Therapy and Radiation Therapy Followed by Docetaxel and Prednisone in Treating Patients With Localized Prostate Cancer
- Effects of IAS in Men With Localized Biochemical Relapsed Prostate Cancer
- Lupron Sex Offender Therapy
- RADAR Trial - Randomised Androgen Deprivation and Radiotherapy
- Hormone Therapy and Ipilimumab in Treating Patients With Advanced Prostate Cancer
- Triptorelin, Flutamide, and External-Beam Radiation Therapy or External-Beam Radiation Therapy Alone in Treating Patients With Stage II or Stage III Prostate Cancer
- Bortezomib With or Without Hormone Therapy in Treating Patients With Relapsed Prostate Cancer
- Hormone Therapy With or Without Docetaxel And Estramustine in Treating Patients With Prostate Cancer That is Locally Advanced or At High Risk of Relapse
- Hormone Therapy and OGX-011 Before Radical Prostatectomy in Treating Patients With Prostate Cancer
- Hormone Therapy Plus Chemotherapy in Treating Patients With Prostate Cancer
- S0032, Combination Chemotherapy Plus Hormone Therapy in Treating Patients With Metastatic Prostate Cancer
- SU5416 Plus Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
- Adjuvant Radiation Therapy Plus Hormone Therapy Compared With Radiation Therapy Alone in Treating Patients With Stage II or Stage III Prostate Cancer
- Androgen Suppression Plus Radiation Therapy in Treating Patients With Prostate Cancer
- Flutamide In the Prevention of Prostate Cancer in Patients With Neoplasia of the Prostate
- Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
- Hormone Therapy Plus Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Prostate Cancer
- Combination Hormone Therapy Followed by Radiation Therapy in Treating Patients With Prostate Cancer
- Hormone Therapy in Treating Patients With Rising PSA Levels Following Radiation Therapy for Prostate Cancer
- Randomized Trial of Adjuvant Hormonal Therapy in Surgically Treated Prostate Cancer Patients at High Risk for Recurrence
- Antineoplaston Therapy in Treating Patients With Stage III or Stage IV Prostate Cancer
- Hormone Therapy in Treating Patients With Prostate Cancer
- Hormone Therapy Plus Radiation Therapy in Treating Patients With Prostate Cancer
- Hormone Therapy in Treating Patients With Advanced Prostate Cancer
- Radiation Therapy With Androgen Suppression in Treating Patients With Prostate Cancer
- Flutamide, Suramin, and Hydrocortisone in Treating Patients With Prostate Cancer
- Chemotherapy Plus Hormone Therapy Versus Androgen Suppression in Treating Patients With Metastatic or Unresectable Prostate Cancer
- Hormone Therapy With or Without Surgery or Radiation Therapy in Treating Patients With Prostate Cancer
- Radiation Therapy With or Without Antiandrogen Therapy in Treating Patients With Stage I or Stage II Prostate Cancer
- Three Drug Combination Therapy Versus Conventional Treatment of Children With Congenital Adrenal Hyperplasia
- A Phase II Trial of Leuprolide + Flutamide + Suramin in Untreated Poor Prognosis Prostate Carcinoma
Clinical trials list
click for details